Literature DB >> 25818831

Response of human lymphocytes to proton radiation of 60 MeV compared to 250 kV X-rays by the cytokinesis-block micronucleus assay.

Justyna Miszczyk1, Kamila Rawojć2, Agnieszka Panek3, Jan Swakoń4, Pataje G Prasanna5, Marzena Rydygier4.   

Abstract

Particle radiotherapy such as protons provides a new promising treatment modality to cancer. However, studies on its efficacy and risks are relatively sparse. Using the cytokinesis-blocked micronucleus assay, we characterized response of human peripheral blood lymphocytes, obtained from health donors irradiated in vitro in the dose range: 0-4. 0 Gy, to therapeutic proton radiation of 60 MeV from AIC-144 isochronous cyclotron, by studying nuclear division index and DNA damage and compared them with X-rays. Peripheral blood lymphocytes show decreased ability to proliferate with increasing radiation doses for both radiation types, however, in contrast to X-rays, irradiation with protons resulted in a higher proliferation index at lower doses of 0.75 and 1.0 Gy. Protons are more effective in producing MN at doses above 1.75 Gy compared to X-rays. Dose-response curves for micronucleus incidence can be best described by a cubic model for protons, while for X-rays the response was linear. The differences in the energy spectrum and intracellular distribution of energy between radiation types are also apparent at the intracellular distribution of cytogenetic damage as seen by the distribution of various numbers of micronuclei in binucleated cells. Our studies, although preliminary, further contribute to the understanding of the mechanistic differences in the response of HPBL in terms of cellular proliferation and cytogenetic damage induced by protons and X-rays as well as intra-cellular distribution of energy and thus radiobiological effectiveness.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cytokinesis-block micronucleus assay; Human lymphocytes; Micronuclei frequency; Nuclear division index; Proton beam; X-rays

Mesh:

Substances:

Year:  2015        PMID: 25818831     DOI: 10.1016/j.radonc.2015.03.003

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  6 in total

Review 1.  The relative biological effectiveness of proton irradiation in dependence of DNA damage repair.

Authors:  Simon Deycmar; Erica Faccin; Tamara Kazimova; Philip A Knobel; Irma Telarovic; Fabienne Tschanz; Verena Waller; Rona Winkler; Carmen Yong; Dario Zingariello; Martin Pruschy
Journal:  Br J Radiol       Date:  2019-11-11       Impact factor: 3.039

2.  Cellular Response to Proton Irradiation: A Simulation Study with TOPAS-nBio.

Authors:  Hongyu Zhu; Aimee L McNamara; Stephen J McMahon; Jose Ramos-Mendez; Nicholas T Henthorn; Bruce Faddegon; Kathryn D Held; Joseph Perl; Junli Li; Harald Paganetti; Jan Schuemann
Journal:  Radiat Res       Date:  2020-07-08       Impact factor: 2.841

3.  Do protons and X-rays induce cell-killing in human peripheral blood lymphocytes by different mechanisms?

Authors:  J Miszczyk; K Rawojć; A Panek; A Borkowska; P G S Prasanna; M M Ahmed; J Swakoń; A Gałaś
Journal:  Clin Transl Radiat Oncol       Date:  2018-01-31

4.  Gold Nanopeanuts as Prospective Support for Cisplatin in Glioblastoma Nano-Chemo-Radiotherapy.

Authors:  Joanna Depciuch; Justyna Miszczyk; Alexey Maximenko; Piotr M Zielinski; Kamila Rawojć; Agnieszka Panek; Pawel Olko; Magdalena Parlinska-Wojtan
Journal:  Int J Mol Sci       Date:  2020-11-29       Impact factor: 5.923

5.  Exploring the differentially expressed genes in human lymphocytes upon response to ionizing radiation: a network biology approach.

Authors:  Tamizh Selvan Gnana Sekaran; Vishakh R Kedilaya; Suchetha N Kumari; Praveenkumar Shetty; Pavan Gollapalli
Journal:  Radiat Oncol J       Date:  2021-03-24

6.  Investigation of DNA Damage and Cell-Cycle Distribution in Human Peripheral Blood Lymphocytes under Exposure to High Doses of Proton Radiotherapy.

Authors:  Justyna Miszczyk
Journal:  Biology (Basel)       Date:  2021-02-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.